Current Report Filing (8-k)
14 4월 2021 - 8:02PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 14, 2021
SYNTHETIC BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)
Nevada
|
|
001-12584
|
|
13-3808303
|
(State or other jurisdiction of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
9605 Medical Center Drive, Suite 270
Rockville, MD 20850
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including
area code: (301) 417-4364
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.001 per share
|
SYN
|
NYSE American
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01
|
|
Regulation FD Disclosure.
|
On April 14, 2021, Synthetic Biologics, Inc. (the “Company”)
issued a press release announcing that enrollment has commenced and the first patient has been dosed in its Phase 1b/2a clinical trial
of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease
(aGVHD). The single-center, randomized, double-blinded, placebo-controlled clinical trial will evaluate the safety, tolerability and potential
absorption into the systemic circulation (if any) of 150 mg oral SYN-004 administered to allogeneic HCT recipients who receive an IV beta-lactam
antibiotic to treat fever. Study participants will be enrolled into three sequential cohorts, with each receiving a different study-assigned
IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN-004 and four will receive placebo. A data readout for the
first cohort is anticipated towards the end of 2021.
A copy of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K.
The information in this Item 7.01 and in the press release attached
as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities
Act of 1933, as amended. The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1 shall not be incorporated
by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such filing.
The press release attached as Exhibit 99.1 includes “safe harbor”
language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein
are “forward-looking” rather than historical. The Company undertakes no duty or obligation to update or revise the information
contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate.
Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press
releases or through other public disclosures.
On April 14, 2021, Synthetic Biologics, Inc. (the “Company”)
issued a press release announcing that enrollment has commenced and the first patient has been dosed in its Phase 1b/2a clinical trial
of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease
(aGVHD). A data readout for the first cohort is anticipated towards the end of 2021.
Item 9.01
|
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 14, 2021
|
SYNTHETIC BIOLOGICS, INC.
|
|
|
|
|
|
By:
|
/s/ Steven A. Shallcross
|
|
|
Name:
|
Steven A. Shallcross
|
|
|
Title:
|
Chief Executive Officer and Chief Financial Officer
|
Synthetic Biologics (AMEX:SYN)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
Synthetic Biologics (AMEX:SYN)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024